Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges.

Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Original Publication: [London] : Nature Pub. Group

Immunization, Secondary*; Antibodies, Viral/*immunology ; BNT162 Vaccine/*immunology ; COVID-19/*immunology ; SARS-CoV-2/*immunology; Adult ; Age Factors ; Aged ; Aged, 80 and over ; COVID-19/epidemiology ; COVID-19/prevention & control ; Female ; Humans ; Immunogenicity, Vaccine ; Longitudinal Studies ; Male ; Middle Aged ; Portugal/epidemiology ; Prospective Studies ; Seroconversion ; Vaccination ; Young Adult

While mRNA vaccines are administrated worldwide in an effort to contain the COVID-19 pandemic, the heterogeneity of the humoral immune response they induce at the population scale remains unclear. Here, in a prospective, longitudinal, cohort-study, including 1245 hospital care workers and 146 nursing home residents scheduled for BNT162b2 vaccination, together covering adult ages from 19 to 99 years, we analyse seroconversion to SARS-CoV-2 spike protein and amount of spike-specific IgG, IgM and IgA before vaccination, and 3-5 weeks after each dose. We show that immunogenicity after a single vaccine dose is biased to IgG, heterogeneous and reduced with increasing age. The second vaccine dose normalizes IgG seroconversion in all age strata. These findings indicate two dose mRNA vaccines is required to reach population scale humoral immunity. The results advocate for the interval between the two doses not to be extended, and for serological monitoring of elderly and immunosuppressed vaccinees.
(© 2022. The Author(s).)

Lancet. 2021 Mar 20;397(10279):1057-1058. (PMID: 33640038)
J Infect Public Health. 2021 Oct;14(10):1560-1562. (PMID: 34247945)
Med. 2021 Mar 12;2(3):281-295.e4. (PMID: 33589885)
Nature. 2020 Aug;584(7819):115-119. (PMID: 32454513)
Sci Rep. 2021 Dec 27;11(1):24448. (PMID: 34961780)
J Clin Invest. 2020 Dec 1;130(12):6477-6489. (PMID: 32833687)
N Engl J Med. 2021 Apr 8;384(14):1372-1374. (PMID: 33691060)
Nat Commun. 2021 Jun 17;12(1):3698. (PMID: 34140469)
PLoS Pathog. 2021 Aug 5;17(8):e1009772. (PMID: 34352039)
JAMA. 2021 Apr 13;325(14):1467-1469. (PMID: 33646292)
Nat Med. 2020 Jul;26(7):1033-1036. (PMID: 32398876)
Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288662)
N Engl J Med. 2021 Jul 1;385(1):90-92. (PMID: 33852796)
Nat Med. 2021 Jun;27(6):981-984. (PMID: 33795870)
Semin Immunol. 2018 Dec;40:83-94. (PMID: 30501873)
Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288661)
N Engl J Med. 2021 Mar 8;384(15):1466-1468. (PMID: 33684280)
BMJ. 2021 Feb 2;372:n308. (PMID: 33531333)
Nat Rev Immunol. 2016 Oct;16(10):626-38. (PMID: 27546235)
Science. 2022 Jan 07;375(6576):43-50. (PMID: 34812653)
Nature. 2020 Aug;584(7821):430-436. (PMID: 32640463)
Nature. 2021 Apr;592(7855):616-622. (PMID: 33567448)
N Engl J Med. 2021 Jun 10;384(23):2259-2261. (PMID: 33822494)
Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089)
N Engl J Med. 2020 Dec 17;383(25):2427-2438. (PMID: 32991794)
Lancet Oncol. 2021 Jun;22(6):765-778. (PMID: 33930323)
Sci Immunol. 2021 Apr 15;6(58):. (PMID: 33858945)
Lancet. 2021 May 15;397(10287):1819-1829. (PMID: 33964222)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
N Engl J Med. 2020 Dec 17;383(25):2439-2450. (PMID: 33053279)

0 (Antibodies, Viral)
N38TVC63NU (BNT162 Vaccine)

Date Created: 20220111 Date Completed: 20220120 Latest Revision: 20240405

20240405

PMC8748650

10.1038/s41467-021-27761-z

35013258